Chester County News and Community Website
Zynerba Pharmaceuticals (NASDAQ: ZYNE), headquartered in Devon, Pennsylvania, is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. The company is committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome, autism spectrum disorder, 22q11.2 deletion syndrome, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies. Learn more at www.zynerba.com and follow them on Twitter at @ZynerbaPharma.
DEVON, PA — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) announced that the Company recently revised its target for reporting topline results from the pivotal Phase 3 RECONNECT trial of Zygel in …
Zynerba Pharmaceuticals Announces Update on RECONNECT, the Phase 3 Trial of Zygel Read More DEVON, PA — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) this week presented positive long-term 38-week data from the Phase 2 INSPIRE trial with Zygel in children and adolescents with 22q11.2 deletion …
Zynerba Pharmaceuticals Announces Positive Long-Term Data from Phase 2 INSPIRE Trial Read More DEVON, PA — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) announced the presentation of a poster at the 61st Annual Meeting of the American College of Neuropsychopharmacology, being held December 4-7, 2022 in …
Zynerba Pharmaceuticals Announces Poster Presentation at the Annual Meeting of the American College of Neuropsychopharmacology Read More DEVON, PA — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) this week announced that the results from the Phase 3 CONNECT-FX study of Zygel for the treatment of behavioral symptoms in children …
Zynerba Pharmaceuticals Announces Publication of Data from Phase 3 CONNECT-FX Study of Zygel Read More DEVON, PA — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) announced that the European Commission (EC) recently granted orphan drug designation to cannabidiol, the active ingredient in its transdermal gel, Zygel™, for …
Zynerba Pharmaceuticals Receives Orphan Drug Designation from European Commission Read More DEVON, PA — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) released reported financial results for the third quarter that ended September 30, 2022, and provided an overview of recent operational highlights and …
Zynerba Pharmaceuticals Reports Third Quarter 2022 Financial Results Read More DEVON, PA — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) announced that the U.S. Patent and Trademark Office recently issued Patent No. 11,458,109, titled “Treatment of 22q11.2 Deletion Syndrome With Cannabidiol,” which …
Zynerba Pharmaceuticals Announces Issuance of New U.S. Patent for Zygel Read More DEVON, PA — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) presented a poster at the recent 2022 National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit in Washington, …
Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome Read More DEVON, PA — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) announced the presentation of a poster at the 2022 National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit …
Zynerba Pharmaceuticals Presents at NORD Conference Read More DEVON, PA — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) announced that the U.S. Patent and Trademark Office recently issued Patent No. 11,458,110, titled “Treatment of Fragile X Syndrome With Cannabidiol,” which …
Zynerba Pharmaceuticals Announces Issuance of New U.S. Patent for Zygel Read More